Drugs / Emixustat
Emixustat
also known as
ACU-4429 · emixustat hydrochloride · ACU-4429 HCL · ACU-4429 HYDROCHLORIDE · ACU-4429, Emixustat HCl · Emixustat HCl
Small molecule targets RPE65 via inhibition
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02130531 | Apr 2014 → Sep 2015 | age-related macular degeneration, diffuse secondary choroid atrophy | Kubota Vision Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00942240 | Jul 2009 → Apr 2010 | — | Kubota Vision Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00703183 | May 2008 → Jun 2009 | — | Kubota Vision Inc. | Completed | No outcome recorded |
| Phase 23 trials · 1 missed | ||||||
| Phase 2 | NCT03033108 | Jan → Nov 2017 | Stargardt disease, degeneration of macula and posterior pole | Kubota Vision Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02753400 | May 2016 → Nov 2017 | proliferative diabetic retinopathy | Kubota Vision Inc. | Completed | Missed primary |
| Phase 2 | NCT01002950 | Oct 2009 → Jun 2012 | diffuse secondary choroid atrophy, dry age related macular degeneration | Kubota Vision Inc. | Completed | No outcome recorded |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT01802866 | Feb 2013 → Apr 2016 | diffuse secondary choroid atrophy | Kubota Vision Inc. | Completed | Missed primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT03772665 | Jan 2019 → Jun 2022 | Stargardt disease | Kubota Vision Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2013-05-09 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Results Acucela and Otsuka Pharmaceutical Announce Phase IIa Clinical Results of Emixustat Hydrochloride (ACU-4429) in Patients with Geographic Atrophy (GA) Associated with Dry Age-related Macular Degeneration (AMD) at ARVO 2013 Annual Meeting otsuka.co.jp ↗
today announced results from a recently completed phase IIa study of emixustat hydrochloride in patients with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD.) |
| 2010-03-17 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Regulatory Otsuka Pharmaceutical and Acucela Receive FDA Fast Track Designation for ACU-4429 in Patients with Dry AMD Novel, Oral Therapy in Phase 2 Clinical Trial for Dry AMD, A Leading Cause of Blindness in People Over Age 50 otsuka.co.jp ↗ |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2013-05-09 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Acucela and Otsuka Pharmaceutical Announce Phase IIa Clinical Results of Emixustat Hydrochloride (ACU-4429) in Patients with Geographic Atrophy (GA) Associated with Dry Age-related Macular Degeneration (AMD) at ARVO 2013 Annual Meeting otsuka.co.jp ↗ |
| 2010-03-17 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka Pharmaceutical and Acucela Receive FDA Fast Track Designation for ACU-4429 in Patients with Dry AMD Novel, Oral Therapy in Phase 2 Clinical Trial for Dry AMD, A Leading Cause of Blindness in People Over Age 50 otsuka.co.jp ↗ |
| 2008-09-04 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Acucela and Otsuka Pharmaceutical Enter Co-Development Agreement for ACU-4429 in Dry Age Related Macular Degeneration otsuka.co.jp ↗ |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Emixustat | “PURPOSE: To determine whether emixustat hydrochloride (emixustat) reduces the rate of enlargement of geographic atrophy (GA) compared with placebo in subjects with age-related...” PMID 29716784 ↗ Apr 2018 |
| Known as | ACU-4429 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00703183 ↗ |
| Known as | ACU-4429 HCL | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107821 ↗ |
| Known as | ACU-4429 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107821 ↗ |
| Known as | ACU-4429, Emixustat HCl | “ACU-4429, Emixustat HCl” NCT02753400 ↗ |
| Known as | Emixustat HCl | “Emixustat HCl Tablet” NCT02130531 ↗ |
| Known as | emixustat hydrochloride | “This is a multi-center, randomized, masked, multiple-dose, crossover study of the pharmacokinetics of emixustat hydrochloride (HCl) in subjects with geographic atrophy (GA)...” NCT02130531 ↗ |
| Action | Inhibit | “RPE65 inhibition” PMID 33214244 ↗ Nov 2020 |
| Modality | Small molecule | “an orally available small molecule” PMID 33214244 ↗ Nov 2020 |
| Route | Oral | “administered as a single dose, orally” NCT00703183 ↗ |
| Target | RPE65 | “targets the retinal pigment epithelium-specific 65 kDa protein (RPE65)” PMID 33214244 ↗ Nov 2020 |